CaliPharms, Inc.
KGET
$0.00
$0.000.00%
09/30/2014 | 06/30/2014 | 03/31/2014 | |||
---|---|---|---|---|---|
Revenue | -- | -- | -- | ||
Total Other Revenue | -- | -- | -- | ||
Total Revenue | -- | -- | -- | ||
Cost of Revenue | -- | -- | -- | ||
Gross Profit | -- | -- | -- | ||
SG&A Expenses | 21.46% | 208.57% | 149.17% | ||
Depreciation & Amortization | -- | -- | -- | ||
Other Operating Expenses | -- | -- | -- | ||
Total Operating Expenses | 57.99% | 305.33% | 168.03% | ||
Operating Income | -25.53% | -242.67% | -153.18% | ||
Income Before Tax | -2,161.95% | -2,375.47% | -493.94% | ||
Income Tax Expenses | -- | -- | -- | ||
Earnings from Continuing Operations | -2,161.95% | -2,375.47% | -493.94% | ||
Earnings from Discontinued Operations | -- | -- | -- | ||
Extraordinary Item & Accounting Change | -- | -- | -- | ||
Minority Interest in Earnings | -- | -- | -- | ||
Net Income | -2,161.95% | -2,375.47% | -493.94% | ||
EBIT | -25.53% | -242.67% | -153.18% | ||
EBITDA | -- | -- | -- | ||
EPS Basic | -- | -- | -- | ||
Normalized Basic EPS | -- | -- | -- | ||
EPS Diluted | -- | -- | -- | ||
Normalized Diluted EPS | -- | -- | -- | ||
Average Basic Shares Outstanding | -- | -- | -- | ||
Average Diluted Shares Outstanding | -- | -- | -- | ||
Dividend Per Share | -- | -- | -- | ||
Payout Ratio | -- | -- | -- |